Long-term Prognosis of Children With Bronchiectasis Treated With Low-dose Erythromycin Intervention
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
According to their compliance, the children were divided into two groups: low dose
erythromycin treated group (erythromycin 3-5mg/kg.d orally for 6 months) and non-erythromycin
treatment group. The quality of life score and acute exacerbation were evaluated during the
observation period (6 months) and one year after the withdrawal of Erythromycin.The pulmonary
imaging changes and the degree of deterioration in pulmonary function were compared between
the two groups.